Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Online-Prähabilitation für Patienten, die auf eine Lebertransplantation warten (OPAL)

2. November 2026 aktualisiert von: University of Alberta

OPAL: Online-Prähabilitation für Patienten, die auf eine Lebertransplantation warten – eine multizentrische, randomisierte, kontrollierte Studie zur Verringerung körperlicher Gebrechlichkeit und zur Verbesserung der Gesundheitsergebnisse

Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.

The proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.

The primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Detaillierte Beschreibung

This multi-centre randomized controlled trial (RCT) will be completed across the six major LT programs in Canada: Vancouver, Edmonton, Calgary, Toronto, London, and Montreal.

Participants involved in this study will be LT transplant candidates with cirrhosis who are receiving care at one of the six participating LT programs.

Participants will be assessed for eligibility, provided informed signed consent, complete baseline testing and then be randomized to the prehabilitation arm or usual care. Participants will be randomized in a 2:1 ratio between groups.

Prehabilitation Arm:

The 12 week prehabilitation program includes exercise, nutrition and psychological components that is accessed through the online digital web platform.

  • The nutrition program includes a nutritional assessment, provision of a daily protein intake target (1.2-1.5 g/kg/day), online group sessions, and follow ups. Participants will also be provided with a clinically tested whey protein powder supplement with dosage based on their malnutrition scoring done at baseline. Follow ups will also be provided based on malnutrition scoring done at baseline.
  • The exercise program includes an exercise assessment, follow along exercise videos, and weekly virtual live exercise sessions. The exercise specialist will advise one of three levels of exercise programming for each participant. Participants will be advised to complete 3 exercise sessions weekly from a combination of virtual group sessions and follow along videos and to participate in planned aerobic activity as much as possible.
  • The weekly acceptance and commitment therapy based educational videos focus on reducing stress and anxiety and improving motivation and adherence.

Control/Usual Care Arm:

This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform. A short questionnaire will be sent to control participants every 4 weeks to track changes in physical activity.

Post-Transplant follow-up In the subgroup of patients who undergo LT, the same in-person and virtual testing will be carried out at 12 weeks post-transplant (timing may vary due to site clinic flow)

Data Collection Plan

Sample size calculations are based on the primary outcome (the chair stand test: time to complete 5 sit-to-stands) using individual data from our local exercise study in cirrhosis (n=59), plus our sit-to-stand data from our study of 694 patients. After accounting for lack of trial completion, loss to follow up, the total sample size is 177, with 59 participants in the control and 118 in the intervention arm.

  1. Quantitative outcomes: Baseline and primary/secondary/exploratory outcome data will be collected with in-person and/or virtual visits at baseline, week 12 (end of trial) and 12 weeks post-transplant (in the subgroup of patients who undergo LT). Charts will be reviewed for information on death, hospitalization, ambulatory care visits, medications and transplantation for up to 2 years after randomization in all participants. Dietary intake data (24-hour recall) may be collected using third party software.
  2. Qualitative data: Interviews/Focus groups will be conducted at the end of the study in a virtual format. Participation in the interviews/focus groups will be optional.

Types of analyses

  1. Quantitative outcomes: Baseline demographic and clinical characteristics will be compared between groups to identify differences that may exist despite randomization. Continuous variables will be screened for assumptions of normality, and descriptive analyses will be presented for participant demographics, medical and outcome variables. Sex will be used in subgroup analysis of primary and secondary outcomes. It will also be a covariate for exploratory analysis in corresponding models. All analyses will adhere to the intention-to-treat principle.
  2. Qualitative data: Qualitative data will be analyzed inductively following a theoretical thematic approach. Data will be coded, with codes combined into larger categories and theme, with the goal of highlighting participant experiences and acceptability (barriers, facilitators) of the OPAL platform and intervention. Data collection and analysis will occur concurrently in order to enable refinement of interview/focus guide questions and deeper exploration of emerging themes.

Primary outcome: The primary outcome (sit to stand test; time to do 5 sit-to-stands) will be analyzed by linear mixed models with random effects, adjusted for baseline score as a covariate. Sites will be entered as random effects.

Secondary/exploratory outcomes: (1) Quantitative outcomes: Similar types of models will be used for continuous secondary/exploratory outcomes. To examine predictors of exercise and nutrition adherence (e.g. COM-B results), generalized linear models with binary outcome will be employed. To evaluate the potential effect of selected demographic variables on outcomes, as an exploratory analysis, models will be adjusted for clinically significant variables (e.g. sex, gender, digital technology proficiency). Results will be primarily descriptive. Exploratory per-protocol analysis will be performed, and the results will be presented if substantial differences are found between this group and the intention-to-treat group.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

179

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alberta
      • Calgary, Alberta, Kanada, T2N 2T9
        • Foothills Medical Centre
      • Edmonton, Alberta, Kanada, T6G1Z1
        • Kaye Edmonton Clinic
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Gordon and Leslie Diamond Health Care Centre
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • London Health Sciences Centre
      • Toronto, Ontario, Kanada, M5G 0A3
        • Toronto General Hospital - Ajmera Transplant Centre
    • Quebec
      • Montreal, Quebec, Kanada, H4A3J1
        • McGill University Health Centre

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.

Exclusion Criteria:

  • Listed for living related donor transplantation with expected time on the wait list <12 weeks, or model for end-stage liver disease (MELD-Na) Score >26 (Justification: time to transplant is very short)
  • Robust status on frailty testing (LFI 0-3.1) (Justification: unlikely to see benefit)
  • Unable to provide informed consent
  • Presence of a clinical condition that makes the intervention unsafe or infeasible (e.g. unable to follow instruction) or unsafe environment for virtual participation
  • Life expectancy less than 6 months, compassionate care (clinician judgment) (Justification: unlikely to see benefit)
  • Recent variceal bleed or history of varices not on adequate prophylaxis (Justification: acute exercise increases portal pressure
  • Transplant indication is cholangiocarcinoma.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Prehabilitation Group

The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention.

12-weeks of online prehabilitation programming including:

1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.

2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).

3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence.

Kein Eingriff: Usual Care

This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in time to do 5-sit-to-stands from baseline
Zeitfenster: Week 0

A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

Week 0
Change in time to do 5-sit-to-stands from baseline
Zeitfenster: Week 12

A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in liver frailty index from baseline
Zeitfenster: Week 0

Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization.

The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index < 3.2, robust; 3.2-4.5, prefrail; and >4.5, frail).

Higher scores mean a worse outcome.

Week 0
Change in liver frailty index from baseline
Zeitfenster: Week 12

Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization.

The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index < 3.2, robust; 3.2-4.5, prefrail; and >4.5, frail).

Higher scores mean a worse outcome.

Week 12
Changes in virtual physical function testing over time (2-min step test)
Zeitfenster: Week 0

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 0
Changes in virtual physical function testing over time (2-min step test)
Zeitfenster: Week 12

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 12
Change in health-related quality of life from baseline (CLDQ)
Zeitfenster: Week 0

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Week 0
Change in health-related quality of life from baseline (CLDQ)
Zeitfenster: Week 12

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Zeitfenster: Week 0

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Week 0
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Zeitfenster: Week 12

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Week 12
Qualitative Acceptability Data
Zeitfenster: Week 12

Inductive analysis of post-trial semi-structured interviews/focus groups with participants

Week 12

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in time to do 5-sit-to-stands from baseline
Zeitfenster: Week 8

A time to complete 5 chair stands of >15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

Completed at week 8 to account for the possibility of transplantation or loss-to-follow-up before the end of the 12 weeks.

Week 8
Change in sarcopenia from baseline
Zeitfenster: Week 0

Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia

Week 0
Change in sarcopenia from baseline
Zeitfenster: Week 12

Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia

Week 12
Change in distance in the 6 minute walk test from baseline
Zeitfenster: Week 0

6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.

Week 0
Change in distance in the 6 minute walk test from baseline
Zeitfenster: Week 12

6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.

Week 12
Change in covert hepatic encephalopathy from baseline
Zeitfenster: Week 0

The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.

Week 0
Change in covert hepatic encephalopathy from baseline
Zeitfenster: Week 12

The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.

Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Zeitfenster: Week 8

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Week 8
Change in health-related quality of life from baseline (CLDQ)
Zeitfenster: Week 8

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Week 8
Change in 6-item COM-B scale over time during intervention
Zeitfenster: Week 4

Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation

Week 4
Change in 6-item COM-B scale over time during intervention
Zeitfenster: Week 8

Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation

Week 8
Change in 6-item COM-B scale over time during intervention
Zeitfenster: Week 12

Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 [strongly disagree] to 7 [strongly agree]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation.

Week 12
Change in health-related quality of life from baseline (EQ5D5L and EQVAS)
Zeitfenster: Post-transplant (12 weeks after transplant date)

The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients.

The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

Post-transplant (12 weeks after transplant date)
Change in health-related quality of life from baseline (CLDQ)
Zeitfenster: Post-transplant (12 weeks after transplant date)

The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis.

Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

Post-transplant (12 weeks after transplant date)
Changes in virtual physical function testing over time (Single leg balance test)
Zeitfenster: Week 0

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 0
Changes in virtual physical function testing over time (Single leg balance test)
Zeitfenster: Week 8

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 8
Changes in virtual physical function testing over time (Single leg balance test)
Zeitfenster: Week 12

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 12
Changes in virtual physical function testing over time (Single leg balance test)
Zeitfenster: Post-transplant (12 weeks after transplant date)

The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance

The literature supports good correlation of this virtual measure when compared to in-person testing

Post-transplant (12 weeks after transplant date)
Changes in virtual physical function testing over time (2-min step test)
Zeitfenster: Week 8

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Week 8
Changes in virtual physical function testing over time (2-min step test)
Zeitfenster: Post-transplant (12 weeks after transplant date)

The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes.

The literature supports good correlation of this virtual measure when compared to in-person testing

Post-transplant (12 weeks after transplant date)
Number of participants who died during the 12 week trial
Zeitfenster: Week 12

Death will be collected through chart review

Week 12
Number of hospitalizations and ambulatory clinic visits during the 12 week trial
Zeitfenster: Week 12

Hospitalizations and ambulatory clinic visits will be collected through chart review

Week 12
Number of participants who were transplanted during the 12 week trial
Zeitfenster: Week 12

Data on transplantations occurring during the trial will be collected through chart review

Week 12
Number of participants who died during the 2 years post-study completion
Zeitfenster: 2 years post-study completion

Death will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

2 years post-study completion
Number of hospitalizations and ambulatory clinic visits during the 2 years post-study completion
Zeitfenster: 2 years post-study completion

Hospitalizations and ambulatory clinic visits will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

2 years post-study completion
Number of participants who were transplanted during the 2 years post-study completion
Zeitfenster: 2 years post-study completion

Data on transplantations occurring during the trial will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

2 years post-study completion
Economic Evaluation
Zeitfenster: Week 12

Healthcare access and hospital usage will be collected through patient survey.

Week 12
Total Length of stay at time of transplant
Zeitfenster: Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain total length of stay at time of transplant

Post-transplant up to 3 months of the trial data collection period
Intensive care unit length of stay at time of post transplant
Zeitfenster: Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain intensive care unit length of stay

Post-transplant up to 3 months of the trial data collection period
Days of mechanical ventilation at time of post transplant
Zeitfenster: Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain days of mechanical ventilation

Post-transplant up to 3 months of the trial data collection period
Discharge location from hospital at time of transplant
Zeitfenster: Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain discharge home from hospital (versus rehabilitation, nursing home or other institutional location)

Post-transplant up to 3 months of the trial data collection period
Readmissions within 30 days at time of transplant
Zeitfenster: Post-transplant up to 3 months of the trial data collection period

In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain any readmissions within 30 days.

Post-transplant up to 3 months of the trial data collection period
Malnutrition
Zeitfenster: Week 0

The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes.

The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).

Week 0
Malnutrition
Zeitfenster: Week 12

The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes.

The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).

Week 12
Adverse events
Zeitfenster: Week 12

Major: death or hospitalization for an event occurring during or up to 3 h after exercise; cardiovascular events (stroke, myocardial infarction); permanent disability; angina, syncope, arrhythmia; variceal bleeding. Minor: hypoglycemia, hyper- or hypotension requiring medical attention, musculoskeletal injury or fall.

Week 12
Changes in health care provider support from baseline
Zeitfenster: Week 0

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 0
Changes in physical activity levels from baseline
Zeitfenster: Week 0

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 0
Changes in health care provider support from baseline
Zeitfenster: Week 4

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 4
Changes in physical activity levels from baseline
Zeitfenster: Week 4

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 4
Changes in health care provider support from baseline
Zeitfenster: Week 8

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 8
Changes in physical activity levels from baseline
Zeitfenster: Week 8

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 8
Changes in health care provider support from baseline
Zeitfenster: Week 12

Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

Week 12
Changes in physical activity levels from baseline
Zeitfenster: Week 12

Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

Week 12
Changes in functional status from baseline
Zeitfenster: Week 0

The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

Week 0
Changes in functional status from baseline
Zeitfenster: Week 8

The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

Week 8
Changes in functional status from baseline
Zeitfenster: Week 12

The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

Week 12
Adherence to prehabilitation program goals
Zeitfenster: Week 12

(i) 70% adherence to target protein intake and protein powder supplementation (assessed by dietary intake, nutrition check ins, platform metrics and monthly nutrition questionnaires), (ii) 70% adherence to exercise sessions (assessed by attendance, check ins, platform metrics) excluding study weeks with interruptions to programming due to health related issues (e.g. transplant dry runs, hospital admissions as these are common in patients awaiting LT)

Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Puneeta Tandon, University of Alberta

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

12. Juli 2023

Primärer Abschluss (Tatsächlich)

28. August 2026

Studienabschluss (Geschätzt)

1. September 2027

Studienanmeldedaten

Zuerst eingereicht

15. Mai 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Juni 2023

Zuerst gepostet (Tatsächlich)

12. Juni 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren